The expanding role of nilotinib in chronic myeloid leukemia
| العنوان: | The expanding role of nilotinib in chronic myeloid leukemia |
|---|---|
| المؤلفون: | Theo D. Kim, Philipp le Coutre |
| المصدر: | Expert Opinion on Drug Safety. 10:97-107 |
| بيانات النشر: | Informa Healthcare, 2010. |
| سنة النشر: | 2010 |
| مصطلحات موضوعية: | Oncology, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, medicine.drug_class, Antineoplastic Agents, medicine.disease_cause, Philadelphia chromosome, Piperazines, Tyrosine-kinase inhibitor, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Internal medicine, Humans, Medicine, Pharmacology (medical), Protein Kinase Inhibitors, Mutation, business.industry, Myeloid leukemia, Imatinib, General Medicine, Protein-Tyrosine Kinases, medicine.disease, Pyrimidines, Protein kinase domain, Nilotinib, Drug Resistance, Neoplasm, Benzamides, Imatinib Mesylate, business, Tyrosine kinase, medicine.drug |
| الوصف: | Several therapeutic options, including tyrosine kinase inhibitors, exist for the treatment of patients with Philadelphia chromosome (Ph)-positive chronic myeloid leukemia (CML). Despite impressive results, there is room for improvement for those patients who are either resistant or intolerant to imatinib.An overview is given on the clinical results with nilotinib, a rationally designed second-generation tyrosine kinase inhibitor, as first- and second-line therapy in patients with Ph-positive CML. Important factors in predicting resistance to nilotinib and guiding therapeutic decisions are addressed.Knowledge on the clinical efficacy and safety of nilotinib after imatinib failure and as first-line treatment. Point mutations in the kinase domain (KD) of BCR-ABL1 are important determinants of clinical sensitivity to currently available tyrosine kinase inhibitors, including nilotinib. Information on specific BCR-ABL1 KD mutations and safety profiles assist in therapeutic decision making.Nilotinib is a highly effective and well-tolerated therapeutic option in patients with Ph-positive CML after imatinib failure. Early evidence demonstrating increased efficacy has allowed expanding nilotinib to previously untreated patients in chronic phase. Insights into mechanisms of resistance to tyrosine kinase inhibitors and predictive factors for response will allow for a more individualized use of these agents. |
| تدمد: | 1744-764X 1474-0338 |
| DOI: | 10.1517/14740338.2011.532486 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81e190d89d1c56774cafb3aba98b6cf0 https://doi.org/10.1517/14740338.2011.532486 |
| رقم الانضمام: | edsair.doi.dedup.....81e190d89d1c56774cafb3aba98b6cf0 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1744764X 14740338 |
|---|---|
| DOI: | 10.1517/14740338.2011.532486 |